Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. [electronic resource]
Producer: 20210614Description: 222-229.e2 p. digitalISSN:- 1938-0682
- Adult
- Aged
- Aged, 80 and over
- Androgens -- blood
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab -- administration & dosage
- Biomarkers, Tumor -- blood
- Docetaxel -- administration & dosage
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Prednisone -- administration & dosage
- Prognosis
- Prostatic Neoplasms, Castration-Resistant -- blood
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.